EUVIMEDEUVIMED entdecken
Crossref

PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy

Felix L Herr, Christian Dascalescu, Matthias P Fabritius, Gabriel T Sheikh, Mathias J Zacherl, Vera Wenter, Lena M Unterrainer, Matthias Brendel, Adrien Holzgreve, Christoph J Auernhammer, Christine Spitzweg, Tanja Burkard und 3 weitere

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.124.268621 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Felix L Herr und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany; felix.herr@med.uni-muenchen.de. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Intestinal Neoplasms, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite well-documented limitations, current guidelines recommend the use of size-based RECIST 1.1 for response assessment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) under radiopharmaceutical therapy (RPT). We hypothesize that functional criteria are superior to RECIST 1.1 for response assessment and progression-free survival (PFS) prediction, and molecular scores can be used in prognosticating PFS.

Methods

This single-center, retrospective study included 178 patients with GEP-NETs (G1 and G2) who were treated with at least 2 consecutive cycles of RPT with [177Lu]Lu-DOTATATE and who underwent somatostatin receptor PET/CT at baseline and after 2 cycles of RPT (follow-up). PFS was defined as the time between baseline and clinical progression, as reported by a GEP-NET multidisciplinary tumor board (MDT) assessment or reported death. The differences in categorization and PFS between RECIST 1.1, Choi (functional criteria), and the MDT were evaluated, and 3-y PFS with MDT defined PFS as the reference. The predictive values of the different scores in somatostatin receptor standardized reporting and data system and Krenning (molecular scores) for PFS were analyzed.

Results

Choi criteria classified a higher number of patients as having progressive disease and partial response and a lower number of patients as having stable disease compared with RECIST 1.1 (P < 0.01). The PFS of patients with progressive disease according to RECIST 1.1 and Choi criteria was shorter than that of patients with stable disease and partial response (P < 0.05). Choi criteria showed a nonsignificantly higher concordance with the MDT than with RECIST 1.1. There was a shift in category from a Krenning score of 4 to a score of 3 between baseline and follow-up (P < 0.01). At baseline, a Krenning score of 3 was associated with a shorter median PFS compared with a score of 4 (P < 0.05).

Conclusion

In addition to RECIST 1.1, further PET- and CT-based imaging criteria have the potential to assess response and predict PFS in patients with GEP-NETs undergoing RPT. Our data support the assumption to use Choi criteria for prediction of PFS and agreement in response assessment. At baseline, the Krenning score can be used to predict therapy response after 2 cycles of RPT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsIntestinal NeoplasmsPositron Emission Tomography Computed TomographyRadiopharmaceuticalsStomach NeoplasmsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedTreatment OutcomeAdultOctreotideOrganometallic CompoundsResponse Evaluation Criteria in Solid TumorsProgression-Free Survival

Stichwörter der Autor:innen

GEP-NETRPTSSTR PET/CThuman studiesresponse criteria

Substanzen

RadiopharmaceuticalsOctreotidelutetium Lu 177 dotatateOrganometallic Compounds

Autor:innen und Institutionen

  • Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany; felix.herr@med.uni-muenchen.de.
  • Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany.
  • Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
  • Bayerisches Zentrum für Krebsforschung, partner site Munich, Munich, Germany.
  • German Center for Neurodegenerative Diseases, Munich, Germany.
  • Munich Cluster for Systems Neurology (SyNergy), University of Munich, Munich, Germany.

Zitieren

APA

Herr, F. L., Dascalescu, C., Fabritius, M. P., Sheikh, G. T., Zacherl, M. J., Wenter, V., Unterrainer, L. M., Brendel, M., Holzgreve, A., Auernhammer, C. J., Spitzweg, C., Burkard, T., Ricke, J., Heimer, M. M., & Cyran, C. C. (2025). PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268621

Vancouver

Herr FL, Dascalescu C, Fabritius MP, Sheikh GT, Zacherl MJ, Wenter V, et al. PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268621

BibTeX
@article{Herr2025,
  author = {Herr, Felix L and Dascalescu, Christian and Fabritius, Matthias P and Sheikh, Gabriel T and Zacherl, Mathias J and Wenter, Vera and Unterrainer, Lena M and Brendel, Matthias and Holzgreve, Adrien and Auernhammer, Christoph J and Spitzweg, Christine and Burkard, Tanja and Ricke, Jens and Heimer, Maurice M and Cyran, Clemens C},
  title = {PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.124.268621}
}
Kostenlos starten →